1. Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome
- Author
-
Barbara Felix, Rolf Handschin, Jürgen Muser, Hans Peter Brunner-Larocca, Ruth von Dahlen, Kaspar Berneis, Jörg Schumann, Stephanie Kiencke, Peter Rickenbacher, University of Zurich, and Rickenbacher, P
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Diabetic Cardiomyopathies ,medicine.drug_class ,10265 Clinic for Endocrinology and Diabetology ,610 Medicine & health ,Left ventricular hypertrophy ,2705 Cardiology and Cardiovascular Medicine ,Muscle hypertrophy ,Electrocardiography ,Ventricular Dysfunction, Left ,Risk Factors ,Internal medicine ,Diabetic cardiomyopathy ,Diabetes mellitus ,Natriuretic Peptide, Brain ,Prevalence ,medicine ,Natriuretic peptide ,Humans ,Mass Screening ,Prospective Studies ,cardiovascular diseases ,Mass screening ,Immunoassay ,business.industry ,Middle Aged ,Prognosis ,medicine.disease ,Brain natriuretic peptide ,Echocardiography, Doppler ,Heart failure ,Cardiology ,Female ,Hypertrophy, Left Ventricular ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies - Abstract
Diabetic cardiomyopathy, characterized by left ventricular (LV) dysfunction and LV hypertrophy independent of myocardial ischaemia and hypertension, could contribute to the increased life-time risk of congestive heart failure seen in patients with diabetes. We assessed prospectively the prevalence, effectiveness of screening methods [brain natriuretic peptide (BNP) and C-reactive protein in combination with clinical parameters], and outcome of pre-clinical diabetic cardiomyopathy.We studied 100 adults (mean age 57.4 +/- 10.2 years, 44% females) with diabetes and no previous evidence of structural heart disease. By echocardiography, diabetic cardiomyopathy was present in 48% of patients. Screening with combinations of clinical parameters (gender, systolic blood pressure, and body mass index), but not BNP, resulted in high negative predictive values for diabetic cardiomyopathy. During a mean follow-up of 48.5 +/- 9.0 months, in the groups with and without diabetic cardiomyopathy, 12.5 vs. 3.9% (P0.2) patients died or experienced cardiovascular events and 37.5 vs. 9.6% (P0.002) had a deterioration in NYHA functional class. Overall event-free survival was 54 vs. 87% (P = 0.001) in the groups with and without diabetic cardiomyopathy, respectively. Brain natriuretic peptide was an independent predictor of events [odds ratio 3.5 (1.1-10.9), P = 0.02].Pre-clinical diabetic cardiomyopathy is common. Screening with combinations of simple clinical parameters, but not BNP, can be useful to identify those patients needing further evaluation. Patients with pre-clinical diabetic cardiomyopathy are at increased risk for functional deterioration and possibly cardiovascular events during follow-up. Brain natriuretic peptide was shown to be an independent predictor of future events.
- Published
- 2010
- Full Text
- View/download PDF